- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Founded in 2006, Anthem Biosciences Ltd provides integrated CRDMO services and specializes in manufacturing specialty ingredients, focusing on both New Chemical Entities and New Biological Entities, with platforms like RNA interference and Antibody-Drug Conjugates.
Anthem Biosciences reported Q1 FY27 revenues of Rs. 418 crores, EBITDA of Rs. 176 crores (40% margin), and PAT of Rs. 120 crores (27.1% margin), with a net cash position of Rs. 1,720 crores. Management acknowledged Q1 was soft due to delivery timing shifts but expressed confidence in full-year recovery...
Anthem Biosciences' Q1FY27 revenue dropped 22.6% YoY to ₹418.2 Cr, with profit after tax falling 11.7% to ₹119.9 Cr. Both CRDMO and Specialty Ingredients segments saw revenue declines. Despite this, the company maintained strong margins, with EBITDA at 39.6% and PAT at 27.1%, showing YoY improvement due to cost discipline....